Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
RESEARCH TOOLSreports
Total Valuation
Zentalis Pharmaceuticals has a market cap or net worth of $109.37M. The enterprise value is $94.00M.
Market Cap$109.37M
Enterprise Value$94.00M
Share Statistics
Zentalis Pharmaceuticals has 71,951,935 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,951,935
Owned by Insiders4.62%
Owned by Institutions38.55%
Financial Efficiency
Zentalis Pharmaceuticals’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -50.69%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-50.69%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee406.17K
Profits Per Employee-999.20K
Employee Count166
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Zentalis Pharmaceuticals is -1.30. Zentalis Pharmaceuticals’s PEG ratio is -0.07.
PE Ratio-1.30
PS Ratio0.00
PB Ratio0.26
Price to Fair Value0.64
Price to FCF-0.52
Price to Operating Cash Flow-0.51
PEG Ratio-0.07
Income Statement
In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M and earned -165.84M in profits. Earnings per share was -2.33.
Revenue67.42M
Gross Profit67.42M
Operating Income-191.19M
Pretax Income-165.69M
Net Income-165.84M
EBITDA-191.19M
Earnings Per Share (EPS)-2.33
Cash Flow
In the last 12 months, operating cash flow was -170.86M and capital expenditures -221.00K, giving a free cash flow of -171.08M billion.
Operating Cash Flow-170.86M
Free Cash Flow-171.08M
Free Cash Flow per Share-2.38
Dividends & Yields
Zentalis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.11
52-Week Price Change-85.45%
50-Day Moving Average1.33
200-Day Moving Average2.51
Relative Strength Index (RSI)63.91
Average Volume (3m)764.19K
Important Dates
Zentalis Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Zentalis Pharmaceuticals as a current ratio of 7.32, with Debt / Equity ratio of 11.74%
Current Ratio7.32
Quick Ratio7.32
Debt to Market Cap0.00
Net Debt to EBITDA-0.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Zentalis Pharmaceuticals has paid 177.00K in taxes.
Income Tax177.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Zentalis Pharmaceuticals EV to EBITDA ratio is -1.16, with an EV/FCF ratio of -1.29.
EV to Sales3.28
EV to EBITDA-1.16
EV to Free Cash Flow-1.29
EV to Operating Cash Flow-1.29
Balance Sheet
Zentalis Pharmaceuticals has $371.08M in cash and marketable securities with $39.58M in debt, giving a net cash position of -$331.51M billion.
Cash & Marketable Securities$371.08M
Total Debt$39.58M
Net Cash-$331.51M
Net Cash Per Share-$4.61
Tangible Book Value Per Share$4.74
Margins
Gross margin is 98.56%, with operating margin of -283.57%, and net profit margin of -245.96%.
Gross Margin98.56%
Operating Margin-283.57%
Pretax Margin-245.74%
Net Profit Margin-245.96%
EBITDA Margin-283.57%
EBIT Margin-278.02%
Analyst Forecast
The average price target for Zentalis Pharmaceuticals is $7.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.13
Price Target Upside369.08% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast48.92%